Trial reportBritish journal of cancer2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Trial report in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151.Journal of gastrointestinal oncology · 2026Article
- Article
- Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.International journal of medical sciences · 2023Review
- Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer.Frontiers in oncology · 2023Article
- Novel approaches in search for biomarkers of cholangiocarcinoma.World journal of gastroenterology · 2022Review
- Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers.ESMO open · 2022Article
- Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma.Frontiers in oncology · 2022Article
- Vimentin-Positive Circulating Tumor Cells as Diagnostic and Prognostic Biomarkers in Patients with Biliary Tract Cancer.Journal of clinical medicine · 2021Article
- Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review.World journal of gastrointestinal oncology · 2021Review
- Next-Generation Biomarkers for Cholangiocarcinoma.Cancers · 2021Review
- Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum.Frontiers in oncology · 2021Review
- Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients.Cancers · 2020Review
- Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer.International journal of cancer · 2020Observational
- Validation and evaluation of a common biomarker in human cancers sera protein detected by a monoclonal antibody UNIVmAb.BMC research notes · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 14 institutions in 1 country.
Funding
Abstract
backgroundAdvanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive biomarkers predictive of cediranib benefit may improve patient outcomes.
methodsChanges in 15 circulating plasma angiogenesis or inflammatory-related proteins and cytokeratin-18 (CK18), measured at baseline and during therapy until disease progression, were correlated with overall survival (OS) using time-varying covariate Cox models (TVC).
resultsSamples were available from n = 117/124 (94%) patients. Circulating Ang1&2, FGFb, PDGFbb, VEGFC, VEGFR1 and CK18 decreased as a result of the therapy, independent of treatment with cediranib. Circulating VEGFR2 and Tie2 were preferentially reduced by cediranib. Patients with increasing levels of VEGFA at any time had a worse PFS and OS; this detrimental effect was attenuated in patients receiving cediranib. TVC analysis revealed CK18 and VEGFR2 increases correlated with poorer OS in all patients (P < 0.001 and P = 0.02, respectively).
conclusionsRising circulating VEGFA levels in patients with ABC, treated with CisGem, are associated with worse PFS and OS, not seen in patients receiving cediranib. Rising levels of markers of tumour burden (CK18) and potential resistance (VEGFR2) are associated with worse outcomes and warrant validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.